Volume | 1,145,585 |
|
|||||
News | - | ||||||
Day High | 5.72 | Low High |
|||||
Day Low | 5.485 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Editas Medicine Inc | EDIT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.68 | 5.485 | 5.72 | 5.53 | 5.62 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,378 | 1,145,585 | $ 5.59 | $ 6,400,853 | - | 4.91 - 11.91 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:02:17 | priorref | 202 | $ 5.52 | USD |
Editas Medicine Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
455.7M | 81.81M | - | 78.12M | -153.22M | -1.87 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Editas Medicine News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EDIT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.43 | 6.69 | 5.40 | 5.80 | 1,875,799 | 0.09 | 1.66% |
1 Month | 5.59 | 6.69 | 4.91 | 5.50 | 1,896,451 | -0.07 | -1.25% |
3 Months | 7.67 | 11.58 | 4.91 | 7.29 | 2,049,869 | -2.15 | -28.03% |
6 Months | 9.85 | 11.69 | 4.91 | 8.32 | 1,906,884 | -4.33 | -43.96% |
1 Year | 9.23 | 11.91 | 4.91 | 8.40 | 1,836,364 | -3.71 | -40.20% |
3 Years | 33.55 | 73.025 | 4.91 | 17.68 | 1,774,150 | -28.03 | -83.55% |
5 Years | 22.17 | 99.95 | 4.91 | 25.02 | 1,543,515 | -16.65 | -75.10% |
Editas Medicine Description
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. |